Korean J Nucl Med.
2000 Aug;34(4):344-352.
Effect of Carrier on Labeling and Biodistribution of Re-188-Hydroxyethylidene
diphosphonate
Abstract
-
PURPOSE: Re-188-Hydroxyethylidene diphosphonate (HEDP) is a new cost-effective agent for
systemic radioisotope therapy of metastatic bone pain. We investigated the influence of
carrier for labeling and biodistribution of Re-188-HEDP using HEDP kit with or without
carrier (KReO4).
MATERALS AND METHODS: The kits (HEDP 15 mg, gentisic acid 4 mg and
SnCl2.2H2O 4.5 mg) with or without carrier (KReO4 0.1 mg) were labeled with Re-188 solution,
made available from an in-house generator by boiling for 15 min. We compared the labeling
efficiency and stability of carrier-added and carrier-free preparations of Re-188-HEDP.
Biodistribution and imaging studies of each preparation were performed in ICR mice
(1.85~3.7 MBq/0.1 ml) and SD rats (74.1~85.2 MBq/0.5 ml).
RESULTS
The carrier-added preparation showed high labeling efficiency (95% at pH 5) and
high stability in serum (88%, 3 hr). However, the carrier-free preparation showed low
labeling efficiency (59% at pH 5) and low stability (43%, 3 hr). The carrier-added preparation
showed high uptake in bone and low uptake in stomach and kidneys. However, the carrier-free
preparation showed lower uptake in bone and higher uptake in both stomach and kidneys, which
is supposed to be due to released perrhenate. The carrier-added preparation also showed better
images with higher skeletal accumulation, lower uptake in other organs and lower soft tissue
uptake than the carrier-free preparation.
CONCLUSION
The results of these studies clearly demonstrate that addition of carrier
perrhenate is required for high labeling efficiency, stability, bone uptake and good
image quality of Re-188-HEDP.